Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 3, 2009, Pages 431-432

  Calcagno, Andrea ^a   Bonora, Stefano ^a   Tettoni, Maria Cristina ^a   D'Avolio, Antonio ^a   Perri, Giovanni Di ^a   Lanzafame, Massimiliano ^b   Penco, Giovanni ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c GALLIERA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; EMTRICITABINE; LAMIVUDINE; TENOFOVIR;

ADULT; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADENINE; ANTI-HIV AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HISTORY, 17TH CENTURY; HIV INFECTIONS; HUMANS; MALE; OLIGOPEPTIDES; PHOSPHONIC ACIDS; PYRIDINES;

EID: 70350528706     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b08f09     Document Type: Letter

References (10)

1. Delfraissy JF, Moreno S, Sanz-Moreno J, et al. Efficacy and safety of 48-week maintenance with QD ATV vs ATV/r (both + 2NRTIs) in patients with VL
2. Malan DR, Krantz E, David N, et al, and 089 Study Group. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2008;47:161-167.
3. McGrath D, Hammond J, Frederick D, et al. Evaluation of resistance patterns in treatment-naive subjects with virological failure on atazanavir-or atazanavir/ritonavir-containing regimens. Antivir Ther. 2006;11:S97
4. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; pp. 1-139. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed February 15, 2009.
5. Atazanavir (Reyataz): new recommendations if combined with tenofovir (Viread)dand warning on Viagra, Cialis, and Levitra. AIDS Treat News 2004;(399):5.
6. Rodŕiguez-Nòvoa S, Morello J, Barreiro P, et al. Switch from ritonavir-boosted to un-boosted atazanavir guided by therapeutic drug monitoring. AIDS Res Hum Retroviruses. 2008;24:821-825.
7. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004;48: 2091-2096.
8. Dailly E, Tribut O, Tattevin P, et al. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinet-ics in HIV-infected patients. Eur J Clin Pharmacol. 2006;62:523-526. E-pub June 9, 2006.
9. Rodriguez-Novoa S, Barreiro P, Rendon A, et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435 C->T polymorphism at the multidrug resistance gene 1. Clin Infect Dis. 2006;42:291-295.
10. Siccardi M, D'Avolio A, Baietto, L, et al. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C->T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis. 2008; 47:1222-1225.